Should you buy Tesla today? Health Score 34, declining revenue (-1%), P/E of 383x and the most negative signal in our coverage: "Avoid New Entries." Honest analysis with real data from May 2026.
Read article →Should you buy Netflix today? Health Score 100, ROE 48.5% and P/FCF of 14.1x rated attractive — but Death Cross confirmed and RSI at 35. Full analysis with real data from May 2026.
Read article →Should you buy MercadoLibre today? RSI oversold (29.3), price near 52-week lows and a "Consider Entry" signal — but 170% debt and negative free cash flow. Full analysis with real data from May 2026.
Read article →AMD or NVIDIA? Full comparison of fundamentals, valuation, technicals and AI signal. NVDA with Health Score 100, 101% ROE and forward P/E of 17x. AMD with Caution Recommended and price already above analyst target. The verdict with real data from May 2026.
Read article →PLTR, APP, UBER, AMD, SHOP, DIS, ABNB and PYPL analyzed and ranked. What to buy, what to wait for and what to avoid according to the full StocksAnalyzer diagnostic: Health Score, AI signal, analyst consensus and Monte Carlo. Clear verdicts with real data.
Read article →Should you buy Shopify today? Positive signal with nuances: 205% earnings growth and price 24.7% below analyst target, but low ROE and forward P/E of 55x still demanding. Clear verdict with real data from May 2026.
Read article →Should you buy Disney today? P/E of 14.9x flagged as undervalued, 87% analyst buy consensus and mostly positive long-term scenario — but 3.1% revenue growth and a Neutral signal. Full analysis with real data from May 2026.
Read article →Should you buy Airbnb today? Positive signal but the most divided consensus of the week: 50% buy versus 45% hold, only 6.7% upside to target and declining earnings. Honest analysis with real data from May 2026.
Read article →Should you buy PayPal today? P/E of 9.3x and EV/EBITDA of 7.3x — the cheapest in all our coverage — but only 23% of analysts recommend buying and -13.6% annually over 2 years. Value trap or real opportunity? Full analysis with real data from May 2026.
Read article →Should you buy Palantir today? Perfect health score, 41.8% revenue growth and 151% annual returns over 2 years — but P/E of 228x and Death Cross confirmed. Clear verdict and real data ahead of May 4 earnings.
Read article →